

## References

I-30

1. Wang X, Yang KH, Wanyan P, et al. Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials. *Oncol Lett.* 2014;7(6):1997-2002.
2. American College of Rheumatology. Denosumab. June 2014.
3. Smith MR, Coleman RE, Klotz L, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. *Ann Oncol.* 2015;26(2):368-74.
4. Leder BZ, Tsai JN, Uihlein AV, et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. *J Clin Endocrinol Metab.* 2014;99(5):1694-700.
5. American Urological Association (AUA). Castration-Resistant Prostate Cancer Guidelines. 2014.
6. De Castro J, García R, Garrido P, et al. Therapeutic potential of denosumab in patients with lung cancer: beyond prevention of skeletal complications. *Clin Lung Cancer.* 2015;16(6):431-46.
7. Lipton A, Fizazi K, Stopeck A, et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. *Eur J Cancer.* 2016;53:75-83.
8. Stopeck AT, Fizazi K, Body JJ, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. *Support Care Cancer.* 2016:447-455.
9. Thosani S, Hu MI. Denosumab: a new agent in the management of hypercalcemia of malignancy. *Future Oncol.* 2015;2865-2871.
10. Prolia (denosumab) [package insert]. Amgen Inc. Thousand Oaks, CA . Revised 07/2019.
11. Xgeva (denosumab) [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 05/2019.
12. Shapiro CL, Moriarty JP, Dusetzine S, et al. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). *J Clin Oncol.* 2017; 35:3949-3955.
13. NCCN Drugs & Biologics Compendium™. Denosumab. 2019. National Comprehensive Cancer Network (NCCN).
14. MICROMEDEX®SOLUTIONS Compendia. 2019. Denosumab.
15. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Denosumab. 2019.
16. Deveci MA, Paydas S, Gonlusen G, et al. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases. *Acta Orthopaedica et*

*Traumatologica Turcica*. 2017;51;1-6.

17. Greenblatt MB, Tsai JN, Wein MN. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. *Clinical Chemistry*. 2017;63(2):464-474.
18. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis and Rheumatology*. 2017;69(8):1521-1537.
19. Tu KN, Lie JD, Wan CKV, et al. Osteoporosis: a review of treatment options. *Pharmacy and Therapeutics*. 2018;43(2):92-104.
20. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 4.2020.